| Menopausal syndrome
Estrogel vs Veozah
Side-by-side clinical, coverage, and cost comparison for menopausal syndrome.Deep comparison between: Estrogel vs Veozah with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVeozah has a higher rate of injection site reactions vs Estrogel based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Veozah but not Estrogel, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Estrogel
Veozah
At A Glance
Topical
Daily
Estrogen
Oral
Daily
NK3 receptor antagonist
Indications
- Menopausal syndrome
- Postmenopausal atrophic vaginitis
- Menopausal syndrome
Dosing
Menopausal syndrome, Postmenopausal atrophic vaginitis EstroGel 0.06% 1.25 g (0.75 mg estradiol) once daily applied as a thin layer over the entire arm on the inside and outside from wrist to shoulder.
Menopausal syndrome 45 mg tablet orally once daily with or without food.
Contraindications
- Abnormal genital bleeding of unknown etiology
- Current or history of breast cancer
- Current or history of estrogen-dependent neoplasia
- Active DVT, PE, or history of these conditions
- Active arterial thromboembolic disease (e.g., stroke or MI), or history of these conditions
- Known anaphylactic reaction, angioedema, or hypersensitivity to EstroGel or any excipient
- Hepatic impairment or disease
- Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
- Known cirrhosis
- Severe renal impairment or end-stage renal disease
- Concomitant use with CYP1A2 inhibitors
Adverse Reactions
Most common (>=5%) Breast pain, headache, flatulence
Serious Cardiovascular disorders, malignant neoplasms
Postmarketing Endometrial cancer, breast cancer, deep vein thrombosis, myocardial ischemia, phlebitis, nausea, alopecia, rash, retinal vein occlusion, meningioma, angioedema, hepatitis
Most common (>=2%) Abdominal pain, diarrhea, insomnia, back pain, hot flush, hepatic transaminase elevation
Serious Hepatic transaminase elevation and hepatotoxicity
Postmarketing Serious drug-induced hepatotoxicity with elevated transaminases, alkaline phosphatase, and bilirubin, coupled with fatigue, nausea, pruritus, jaundice, pale feces, and dark urine
Pharmacology
Estradiol is the principal intracellular human estrogen, acting through binding to nuclear receptors in estrogen-responsive tissues; it modulates pituitary gonadotropin secretion via a negative feedback mechanism to reduce elevated LH and FSH levels seen in postmenopausal women.
Fezolinetant is an NK3 receptor antagonist that blocks neurokinin B binding on kisspeptin/neurokinin B/dynorphin neurons to modulate neuronal activity in the thermoregulatory center, with >450-fold selectivity for NK3 over NK1 or NK2 receptors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Estrogel
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (9/12)
Veozah
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (10/12)
UnitedHealthcare
Estrogel
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Veozah
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (6/8)
Humana
Estrogel
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Veozah
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Estrogel.
No savings programs available for Veozah.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EstrogelView full Estrogel profile
VeozahView full Veozah profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.